These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

846 related articles for article (PubMed ID: 33534108)

  • 1. Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?
    Chaves Filho AJM; Gonçalves F; Mottin M; Andrade CH; Fonseca SNS; Macedo DS
    J Neuroimmune Pharmacol; 2021 Jun; 16(2):213-218. PubMed ID: 33534108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetracyclines, a promise for neuropsychiatric disorders: from adjunctive therapy to the discovery of new targets for rational drug design in psychiatry.
    Chaves Filho AJM; Mottin M; Soares MV; Jucá PM; Andrade CH; Macedo DS
    Behav Pharmacol; 2021 Apr; 32(2&3):123-141. PubMed ID: 33595954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.
    Jansen van Vuren E; Steyn SF; Brink CB; Möller M; Viljoen FP; Harvey BH
    Biomed Pharmacother; 2021 Mar; 135():111200. PubMed ID: 33421734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.
    Bortolanza M; Nascimento GC; Socias SB; Ploper D; Chehín RN; Raisman-Vozari R; Del-Bel E
    J Neural Transm (Vienna); 2018 Oct; 125(10):1403-1415. PubMed ID: 30109452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications.
    Garrido-Mesa J; Adams K; Galvez J; Garrido-Mesa N
    Expert Opin Investig Drugs; 2022 May; 31(5):475-482. PubMed ID: 35294307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines.
    Lai AY; Todd KG
    Glia; 2006 Jun; 53(8):809-16. PubMed ID: 16541436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?
    Singh H; Chauhan P; Singh J; Saurabh ; Gautam CS; Kakkar AK
    Expert Rev Clin Pharmacol; 2021 Mar; 14(3):315-322. PubMed ID: 33586566
    [No Abstract]   [Full Text] [Related]  

  • 9. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
    Akilesh SM; J R; Palanisamy D; Wadhwani A
    Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications.
    Ong WY; Go ML; Wang DY; Cheah IK; Halliwell B
    Mol Neurobiol; 2021 Jan; 58(1):106-117. PubMed ID: 32897518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
    Wang J
    J Chem Inf Model; 2020 Jun; 60(6):3277-3286. PubMed ID: 32315171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug repurposing for COVID-19 based on an integrative meta-analysis of SARS-CoV-2 induced gene signature in human airway epithelium.
    Gupta RK; Nwachuku EL; Zusman BE; Jha RM; Puccio AM
    PLoS One; 2021; 16(9):e0257784. PubMed ID: 34582497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug repurposing and cytokine management in response to COVID-19: A review.
    Heimfarth L; Serafini MR; Martins-Filho PR; Quintans JSS; Quintans-Júnior LJ
    Int Immunopharmacol; 2020 Nov; 88():106947. PubMed ID: 32919216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.
    Yousefi H; Mashouri L; Okpechi SC; Alahari N; Alahari SK
    Biochem Pharmacol; 2021 Jan; 183():114296. PubMed ID: 33191206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
    Goel B; Bhardwaj N; Tripathi N; Jain SK
    Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposing Psychotropic Agents for Viral Disorders: Beyond Covid.
    Golden SR; Rosenstein DL; Belhorn T; Blatt J
    Assay Drug Dev Technol; 2021; 19(6):373-385. PubMed ID: 34375133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposing Existing Drugs for the Treatment of COVID-19.
    Farne H; Kumar K; Ritchie AI; Finney LJ; Johnston SL; Singanayagam A
    Ann Am Thorac Soc; 2020 Oct; 17(10):1186-1194. PubMed ID: 32692580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.